A Phase 2 interventional study of BNT162b2 in SARS-CoV-2 Infection, COVID19, sponsored by BioNTech SE. Completed at 30 sites in 4 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by BioNTech SE · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 45th largest by enrollment, is one of 30 that started in 2021, is one of 16 in phase 2, and was the 14th registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 32nd largest by enrollment, is one of 10 that started in 2021, is one of 6 in phase 2, and was the 17th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised. Participants are going to be followed up for 6 months after dose 4, and each participant is projected to be on the study for approximately 15 months. This study will be conducted in the United States, Brazil, Germany and Mexico.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who are by virtue of the following:
Having known non-small cell lung cancer (NSCLC) and is ≥18 years of age with at least 1 of the following:
Having known chronic lymphocytic leukemia (CLL) and is ≥18 years of age with at least 1 of the following:
Is on active immunomodulator therapy (eg, tumor necrosis factor alpha (TNFα) inhibitor, or tofacitinib or methotrexate) for an or inflammatory disease disorder (eg, inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis, and inflammatory bowel disease, such as ulcerative colitis and Crohn's disease) at a stable* dose
*Stable dose is defined as receiving the same dose for at least 3 months (84 days) with no changes in the 28 days prior to Visit 1; or
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intramuscular Injection
Biological: BNT162b2
Intramuscular Injection
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided confidence intervals (CIs) were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 Evaluable Immunogenicity population (EIP).
Time frame: 1 Month after Vaccination 3
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.
Time frame: 1 Month after Vaccination 3
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.
Time frame: 1 Month after Vaccination 3
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.
Time frame: 1 Month after Vaccination 3
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.
Time frame: 1 Month after Vaccination 4
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.
Time frame: 1 Month after Vaccination 4
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.
Time frame: 1 Month after Vaccination 4
GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP .
Time frame: 1 Month after Vaccination 4
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years
Local reactions were collected in an electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\>0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years
Local reactions collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate(\>2.0 to 7.0 cm), severe(\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis\[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity),Grade 4(ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate(\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity) and Grade 4(ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting Local Reactions by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=2 to <5 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 degree C (deg C); categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=5 to <12 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=12 to <18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 1 in Participants Aged >=18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 1
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=2 to <5 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=5 to <12 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=12 to <18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 2 in Participants Aged >=18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 2
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=2 to <5 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=5 to <12 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=12 to <18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 3 in Participants Aged >=18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 3
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=2 to <5 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=5 to <12 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 de, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=12 to <18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting Systemic Events by Maximum Severity Within 7 Days After Vaccination 4 in Participants Aged >=18 Years
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
Time frame: Day 1 to Day 7 after Vaccination 4
Percentage of Participants Reporting at Least 1 Adverse Event (AE) After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=2 to <5 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 1 to 1 month after Vaccination 2
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=5 to <12 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 1 to 1 month after Vaccination 2
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=12 to <18 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 1 to 1 month after Vaccination 2
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=18 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 1 to 1 month after Vaccination 2
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 3 to 1 month after Vaccination 3
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 3 to 1 month after Vaccination 3
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=12 to <18 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 3 to 1 month after Vaccination 3
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=18 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 3 to 1 month after Vaccination 3
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 4 to 1 month after Vaccination 4
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 4 to 1 month after Vaccination 4
Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=12 to <18 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 4 to 1 month after Vaccination 4
Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=18 Years
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From Vaccination 4 to 1 month after Vaccination 4
Percentage of Participants Reporting Serious Adverse Events (SAEs) From Vaccination 1 Through the Duration of the Study in Participants Aged >=2 to <5 Years
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=5 to <12 Years
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=12 to <18 Years
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
Percentage of Participants Reporting SAEs From Dose 1 Through the Duration of the Study in Participants Aged >=18 Years
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
Time frame: From Vaccination 1 to 6 months after Vaccination 4 (approximately 14 months)
| Milestone | (Greater Than or Equal to (>=) 2 to Less Than (<) 5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 9 | 15 | 13 | 19 | 24 | 22 | 7 | 1 | 7 | 5 | 1 | 1 |
| Dose 1 | 9 | 15 | 13 | 19 | 24 | 22 | 7 | 1 | 7 | 5 | 1 | 1 |
| Dose 2 | 9 | 15 | 12 | 19 | 24 | 22 | 7 | 1 | 7 | 5 | 1 | 1 |
| Dose 3 | 9 | 15 | 11 | 17 | 24 | 22 | 7 | 1 | 6 | 5 | 1 | 1 |
| Dose 4 | 7 | 13 | 6 | 14 | 20 | 17 | 5 | 1 | 3 | 3 | 1 | 0 |
| Completed | 7 | 12 | 6 | 16 | 20 | 18 | 5 | 0 | 3 | 3 | 1 | 0 |
| Not completed | 2 | 3 | 7 | 3 | 4 | 4 | 2 | 1 | 4 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by parent/guardian | 2 | 3 | 3 | 1 | 3 | 2 | 1 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Refused further study procedures | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GMTs and corresponding 2-sided confidence intervals (CIs) were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 Evaluable Immunogenicity population (EIP).
| Titers | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | 600.2 (77.8 to 4629.8) | 884.7 (176.7 to 4430.6) | — |
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.
| Titers | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | 758.4 (123.7 to 4650.4) | 741.2 (150.6 to 3647.0) | 4592.3 (1989.5 to 10600.4) |
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.
| Titers | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | 7330.0 (NA to NA) | 43.5 (NA to NA) | 2368.1 (1679.9 to 3338.3) |
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 3 EIP.
| Titers | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 3 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | 596.5 (0.1 to 3699753.4) | — | 115.0 (NA to NA) |
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.
| Titers | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | 837.5 (1.4 to 518774.5) | 9576.3 (0.0 to 2070132632.7) | — |
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.
| Titers | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | 754.2 (0.0 to 351878145.2) | 5335.3 (517.0 to 55061.8) | 5330.8 (0.0 to 113927797661576) |
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below LLOQ were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP.
| Titers | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged 12 to <18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | — | 2845.0 (NA to NA) | — |
GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution). Assay results below lower limit of quantification (LLOQ) were set to 0.5\*LLOQ. Participants who had no serological or virological evidence (prior to the subsequent blood sample collection) of past SARS-CoV-2 infection (i.e, negative N-binding antibody \[serum\] result at any visit prior to subsequent time point, SARS-CoV-2 not detected by NAAT \[nasal swab\] until prior vaccination, and negative NAAT \[nasal swab\] result at any unscheduled visit prior to subsequent blood sample collection) and had no medical history of COVID-19 were included in the analysis. Analysis was performed in Dose 4 EIP .
| Titers | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| GMTs of SARS-CoV-2 Neutralizing Titers at 1 Month After Vaccination 4 in Participants Aged >=18 Years Without Serological or Virological Evidence of Past SARS-CoV-2 Infection | 1474.0 (NA to NA) | — | — |
Local reactions were collected in an electronic diary (e-diary) or during unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\>0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 11.1 ± 0.3 | 6.7 ± 0.2 | 0 ± 0.0 |
| Redness: Mild | 11.1 ± 0.3 | 6.7 ± 0.2 | 0 ± 0.0 |
| Redness: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Any | 11.1 ± 0.3 | 13.3 ± 1.7 | 23.1 ± 5.0 |
| Pain at the injection site: Mild | 11.1 ± 0.3 | 13.3 ± 1.7 | 23.1 ± 5.0 |
| Pain at the injection site: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 10.5 ± 1.3 | 8.3 ± 1.0 | 9.1 ± 1.1 |
| Redness: Mild | 10.5 ± 1.3 | 4.2 ± 0.1 | 4.5 ± 0.1 |
| Redness: Moderate | 0 ± 0.0 | 4.2 ± 0.1 | 4.5 ± 0.1 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 5.3 ± 0.1 | 4.2 ± 0.1 | 18.2 ± 5.2 |
| Swelling: Mild | 5.3 ± 0.1 | 0 ± 0.0 | 13.6 ± 2.9 |
| Swelling: Moderate | 0 ± 0.0 | 4.2 ± 0.1 | 4.5 ± 0.1 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Any | 73.7 ± 48.8 | 58.3 ± 36.6 | 54.5 ± 32.2 |
| Pain at the injection site: Mild | 52.6 ± 28.9 | 50.0 ± 29.1 | 45.5 ± 24.4 |
| Pain at the injection site: Moderate | 21.1 ± 6.1 | 8.3 ± 1.0 | 9.1 ± 1.1 |
| Pain at the injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 28.6 ± 3.7 | 0 ± 0.0 | 14.3 ± 0.4 |
| Redness: Mild | 28.6 ± 3.7 | 0 ± 0.0 | 14.3 ± 0.4 |
| Redness: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 28.6 ± 3.7 | 100.0 ± 2.5 | 14.3 ± 0.4 |
| Swelling: Mild | 0 ± 0.0 | 100.0 ± 2.5 | 0 ± 0.0 |
| Swelling: Moderate | 28.6 ± 3.7 | 0 ± 0.0 | 14.3 ± 0.4 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Any | 85.7 ± 42.1 | 100.0 ± 2.5 | 57.1 ± 18.4 |
| Pain at the injection site: Mild | 71.4 ± 29.0 | 100.0 ± 2.5 | 28.6 ± 3.7 |
| Pain at the injection site: Moderate | 14.3 ± 0.4 | 0 ± 0.0 | 28.6 ± 3.7 |
| Pain at the injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at the injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 1. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Redness: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Any | 80.0 ± 28.4 | 100.0 ± 2.5 | 100.0 ± 2.5 |
| Pain at injection site: Mild | 40.0 ± 5.3 | 100.0 ± 2.5 | 0 ± 0.0 |
| Pain at injection site: Moderate | 40.0 ± 5.3 | 0 ± 0.0 | 100.0 ± 2.5 |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate(\>2.0 to 7.0 cm), severe(\>7.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis\[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity),Grade 4(ER visit or hospitalization for severe pain at injection site).Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 0 (0.0 to 30.8) |
| Redness: Mild | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 0 (0.0 to 30.8) |
| Redness: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Redness: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Redness: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Swelling: Any | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 0 (0.0 to 30.8) |
| Swelling: Mild | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 0 (0.0 to 30.8) |
| Swelling: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Swelling: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Swelling: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Pain at injection site: Any | 11.1 (0.3 to 48.2) | 20.0 (4.3 to 48.1) | 9.1 (0.2 to 41.3) |
| Pain at injection site: Mild | 11.1 (0.3 to 48.2) | 20.0 (4.3 to 48.1) | 9.1 (0.2 to 41.3) |
| Pain at injection site: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 28.5) |
| Pain at injection site: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 28.5) |
| Pain at injection site: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 28.5) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 10.5 ± 1.3 | 12.5 ± 2.7 | 22.7 ± 7.8 |
| Redness: Mild | 10.5 ± 1.3 | 4.2 ± 0.1 | 13.6 ± 2.9 |
| Redness: Moderate | 0 ± 0.0 | 8.3 ± 1.0 | 9.1 ± 1.1 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 10.5 ± 1.3 | 8.3 ± 1.0 | 31.8 ± 13.9 |
| Swelling: Mild | 10.5 ± 1.3 | 4.2 ± 0.1 | 9.1 ± 1.1 |
| Swelling: Moderate | 0 ± 0.0 | 4.2 ± 0.1 | 22.7 ± 7.8 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Any | 68.4 ± 43.4 | 62.5 ± 40.6 | 50.0 ± 28.2 |
| Pain at injection site: Mild | 52.6 ± 28.9 | 45.8 ± 25.6 | 22.7 ± 7.8 |
| Pain at injection site: Moderate | 15.8 ± 3.4 | 16.7 ± 4.7 | 27.3 ± 10.7 |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 16.7 (0.4 to 64.1) |
| Redness: Mild | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 16.7 (0.4 to 64.1) |
| Redness: Moderate | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Redness: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Redness: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Any | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 16.7 (0.4 to 64.1) |
| Swelling: Mild | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 16.7 (0.4 to 64.1) |
| Swelling: Moderate | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Pain at injection site: Any | 85.7 (42.1 to 99.6) | 100.0 (2.5 to 100.0) | 57.1 (18.4 to 90.1) |
| Pain at injection site: Mild | 57.1 (18.4 to 90.1) | 100.0 (2.5 to 100.0) | 28.6 (3.7 to 71.0) |
| Pain at injection site: Moderate | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 28.6 (3.7 to 71.0) |
| Pain at injection site: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 41.0) |
| Pain at injection site: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 41.0) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 2. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Redness: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Any | 80.0 ± 28.4 | 100.0 ± 2.5 | 0 ± 0.0 |
| Pain at injection site: Mild | 60.0 ± 14.7 | 100.0 ± 2.5 | 0 ± 0.0 |
| Pain at injection site: Moderate | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 11.1 ± 0.3 | 13.3 ± 1.7 | 0 ± 0.0 |
| Redness: Mild | 0 ± 0.0 | 6.7 ± 0.2 | 0 ± 0.0 |
| Redness: Moderate | 11.1 ± 0.3 | 6.7 ± 0.2 | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 11.1 ± 0.3 | 6.7 ± 0.2 | 0 ± 0.0 |
| Swelling: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Moderate | 11.1 ± 0.3 | 6.7 ± 0.2 | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Any | 22.2 ± 2.8 | 13.3 ± 1.7 | 9.1 ± 0.2 |
| Pain at injection site: Mild | 0 ± 0.0 | 13.3 ± 1.7 | 9.1 ± 0.2 |
| Pain at injection site: Moderate | 22.2 ± 2.8 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 29.4 ± 10.3 | 4.3 ± 0.1 | 14.3 ± 3.0 |
| Redness: Mild | 17.6 ± 3.8 | 0 ± 0.0 | 9.5 ± 1.2 |
| Redness: Moderate | 11.8 ± 1.5 | 4.3 ± 0.1 | 4.8 ± 0.1 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 17.6 ± 3.8 | 8.7 ± 1.1 | 14.3 ± 3.0 |
| Swelling: Mild | 5.9 ± 0.1 | 0 ± 0.0 | 9.5 ± 1.2 |
| Swelling: Moderate | 11.8 ± 1.5 | 8.7 ± 1.1 | 4.8 ± 0.1 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Any | 70.6 ± 44.0 | 26.1 ± 10.2 | 57.1 ± 34.0 |
| Pain at injection site: Mild | 35.3 ± 14.2 | 21.7 ± 7.5 | 42.9 ± 21.8 |
| Pain at injection site: Moderate | 35.3 ± 14.2 | 4.3 ± 0.1 | 14.3 ± 3.0 |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild \>2.0 to 5.0 cm), moderate(\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate(interfered with activity), severe(prevented daily activity) and Grade 4(ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Redness: Mild | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Redness: Moderate | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Redness: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Redness: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Any | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Mild | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Moderate | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Swelling: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Pain at injection site: Any | 71.4 (29.0 to 96.3) | 100.0 (2.5 to 100.0) | 66.7 (22.3 to 95.7) |
| Pain at injection site: Mild | 28.6 (3.7 to 71.0) | 100.0 (2.5 to 100.0) | 33.3 (4.3 to 77.7) |
| Pain at injection site: Moderate | 42.9 (9.9 to 81.6) | 0 (0.0 to 97.5) | 33.3 (4.3 to 77.7) |
| Pain at injection site: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Pain at injection site: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 3. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Redness: Any | 25.0 ± 0.6 | — | 0 ± 0.0 |
| Redness: Mild | 25.0 ± 0.6 | — | 0 ± 0.0 |
| Redness: Moderate | 0 ± 0.0 | — | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | — | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | — | 0 ± 0.0 |
| Swelling: Any | 25.0 ± 0.6 | — | 0 ± 0.0 |
| Swelling: Mild | 25.0 ± 0.6 | — | 0 ± 0.0 |
| Swelling: Moderate | 0 ± 0.0 | — | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | — | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | — | 0 ± 0.0 |
| Pain at injection site: Any | 75.0 ± 19.4 | — | 0 ± 0.0 |
| Pain at injection site: Mild | 50.0 ± 6.8 | — | 0 ± 0.0 |
| Pain at injection site: Moderate | 25.0 ± 0.6 | — | 0 ± 0.0 |
| Pain at injection site: Severe | 0 ± 0.0 | — | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | — | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 28.6 ± 3.7 | 16.7 ± 0.4 | 0 ± 0.0 |
| Redness: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Moderate | 14.3 ± 0.4 | 16.7 ± 0.4 | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 14.3 ± 0.4 | 0 ± 0.0 | 16.7 ± 0.4 |
| Swelling: Mild | 0 ± 0.0 | 0 ± 0.0 | 16.7 ± 0.4 |
| Swelling: Moderate | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Any | 28.6 ± 3.7 | 0 ± 0.0 | 16.7 ± 0.4 |
| Pain at injection site: Mild | 28.6 ± 3.7 | 0 ± 0.0 | 16.7 ± 0.4 |
| Pain at injection site: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4.Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\>0.5 to 2.0 cm),moderate (\>2.0 to 7.0 cm), severe (\>7.0 cm) and Grade 4(necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 8.3 ± 0.2 | 5.3 ± 0.1 | 20.0 ± 4.3 |
| Redness: Mild | 8.3 ± 0.2 | 5.3 ± 0.1 | 6.7 ± 0.2 |
| Redness: Moderate | 0 ± 0.0 | 0 ± 0.0 | 13.3 ± 1.7 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Any | 16.7 ± 2.1 | 5.3 ± 0.1 | 20.0 ± 4.3 |
| Swelling: Mild | 8.3 ± 0.2 | 5.3 ± 0.1 | 13.3 ± 1.7 |
| Swelling: Moderate | 8.3 ± 0.2 | 0 ± 0.0 | 6.7 ± 0.2 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Any | 91.7 ± 61.5 | 42.1 ± 20.3 | 40.0 ± 16.3 |
| Pain at injection site: Mild | 41.7 ± 15.2 | 31.6 ± 12.6 | 26.7 ± 7.8 |
| Pain at injection site: Moderate | 50.0 ± 21.1 | 10.5 ± 1.3 | 13.3 ± 1.7 |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Redness: Any | 75.0 (19.4 to 99.4) | 0 (0.0 to 97.5) | 66.7 (9.4 to 99.2) |
| Redness: Mild | 75.0 (19.4 to 99.4) | 0 (0.0 to 97.5) | 66.7 (9.4 to 99.2) |
| Redness: Moderate | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Redness: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Redness: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Swelling: Any | 50.0 (6.8 to 93.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Swelling: Mild | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Swelling: Moderate | 50.0 (6.8 to 93.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Swelling: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Swelling: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Pain at injection site: Any | 75.0 (19.4 to 99.4) | 100.0 (2.5 to 100.0) | 33.3 (0.8 to 90.6) |
| Pain at injection site: Mild | 25.0 (0.6 to 80.6) | 100.0 (2.5 to 100.0) | 0 (0.0 to 70.8) |
| Pain at injection site: Moderate | 50.0 (6.8 to 93.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Pain at injection site: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Pain at injection site: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
Local reactions were collected in e-diary or during unscheduled clinical assessments from Day 1 to Day 7 after vaccination 4. Redness and swelling were measured and recorded in mdu where, 1 mdu =0.5 cm and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Reactions reported as adverse events in case report form within 7 days of study vaccination were also included. Two-sided 95% CI was based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Redness: Any | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Redness: Mild | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Redness: Moderate | 0 ± 0.0 | 0 ± 0.0 | — |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Redness: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| Swelling: Any | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Swelling: Mild | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Swelling: Moderate | 0 ± 0.0 | 0 ± 0.0 | — |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Swelling: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| Pain at injection site: Any | 66.7 ± 9.4 | 100.0 ± 2.5 | — |
| Pain at injection site: Mild | 33.3 ± 0.8 | 100.0 ± 2.5 | — |
| Pain at injection site: Moderate | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Pain at injection site: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Pain at injection site: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 degree C (deg C); categorized as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 0 ± 0.0 | 0 ± 0.0 | 15.4 ± 1.9 |
| Fever: >=38.0 to 38.4 deg C | 0 ± 0.0 | 0 ± 0.0 | 7.7 ± 0.2 |
| Fever: >38.4 to 38.9 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 to 40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 7.7 ± 0.2 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 22.2 ± 2.8 | 6.7 ± 0.2 | 7.7 ± 0.2 |
| Fatigue: Mild | 11.1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Moderate | 11.1 ± 0.3 | 6.7 ± 0.2 | 7.7 ± 0.2 |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 11.1 ± 0.3 | 0 ± 0.0 | 7.7 ± 0.2 |
| Chills: Mild | 11.1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Moderate | 0 ± 0.0 | 0 ± 0.0 | 7.7 ± 0.2 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 11.1 ± 0.3 | 0 ± 0.0 | 23.1 ± 5.0 |
| Vomiting: Mild | 11.1 ± 0.3 | 0 ± 0.0 | 7.7 ± 0.2 |
| Vomiting: Moderate | 0 ± 0.0 | 0 ± 0.0 | 15.4 ± 1.9 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 0 ± 0.0 | 20.0 ± 4.3 | 7.7 ± 0.2 |
| Diarrhea: Mild | 0 ± 0.0 | 20.0 ± 4.3 | 0 ± 0.0 |
| Diarrhea: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 7.7 ± 0.2 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 11.1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Moderate | 11.1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 11.1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Moderate | 11.1 ± 0.3 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 0 (0.0 to 17.6) | 4.2 (0.1 to 21.1) | 0 (0.0 to 15.4) |
| Fever: >=38.0 to 38.4 deg C | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 17.6) | 4.2 (0.1 to 21.1) | 0 (0.0 to 15.4) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Fever: >40.0 deg C | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Fatigue: Any | 47.4 (24.4 to 71.1) | 37.5 (18.8 to 59.4) | 22.7 (7.8 to 45.4) |
| Fatigue: Mild | 31.6 (12.6 to 56.6) | 20.8 (7.1 to 42.2) | 13.6 (2.9 to 34.9) |
| Fatigue: Moderate | 15.8 (3.4 to 39.6) | 16.7 (4.7 to 37.4) | 9.1 (1.1 to 29.2) |
| Fatigue: Severe | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Fatigue: Grade 4 | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Headache: Any | 42.1 (20.3 to 66.5) | 12.5 (2.7 to 32.4) | 22.7 (7.8 to 45.4) |
| Headache: Mild | 31.6 (12.6 to 56.6) | 12.5 (2.7 to 32.4) | 9.1 (1.1 to 29.2) |
| Headache: Moderate | 10.5 (1.3 to 33.1) | 0 (0.0 to 14.2) | 13.6 (2.9 to 34.9) |
| Headache: Severe | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Headache: Grade 4 | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Chills: Any | 5.3 (0.1 to 26.0) | 0 (0.0 to 14.2) | 4.5 (0.1 to 22.8) |
| Chills: Mild | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 4.5 (0.1 to 22.8) |
| Chills: Moderate | 5.3 (0.1 to 26.0) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Chills: Severe | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Chills: Grade 4 | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Vomiting: Any | 5.3 (0.1 to 26.0) | 4.2 (0.1 to 21.1) | 0 (0.0 to 15.4) |
| Vomiting: Mild | 5.3 (0.1 to 26.0) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Vomiting: Moderate | 0 (0.0 to 17.6) | 4.2 (0.1 to 21.1) | 0 (0.0 to 15.4) |
| Vomiting: Severe | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Vomiting: Grade 4 | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Diarrhea: Any | 10.5 (1.3 to 33.1) | 0 (0.0 to 14.2) | 4.5 (0.1 to 22.8) |
| Diarrhea: Mild | 10.5 (1.3 to 33.1) | 0 (0.0 to 14.2) | 4.5 (0.1 to 22.8) |
| Diarrhea: Moderate | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Diarrhea: Severe | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| Diarrhea: Grade 4 | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened muscle pain: Any | 5.3 (0.1 to 26.0) | 4.2 (0.1 to 21.1) | 0 (0.0 to 15.4) |
| New or worsened muscle pain: Mild | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened muscle pain: Moderate | 5.3 (0.1 to 26.0) | 4.2 (0.1 to 21.1) | 0 (0.0 to 15.4) |
| New or worsened muscle pain: Severe | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened joint pain: Any | 10.5 (1.3 to 33.1) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened joint pain: Mild | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened joint pain: Moderate | 10.5 (1.3 to 33.1) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened joint pain: Severe | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 17.6) | 0 (0.0 to 14.2) | 0 (0.0 to 15.4) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >=38.0 deg C to 38.4 deg C | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 deg C to 38.9 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 deg C to 40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 57.1 ± 18.4 | 0 ± 0.0 | 42.9 ± 9.9 |
| Fatigue: Mild | 0 ± 0.0 | 0 ± 0.0 | 14.3 ± 0.4 |
| Fatigue: Moderate | 57.1 ± 18.4 | 0 ± 0.0 | 28.6 ± 3.7 |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 42.9 ± 9.9 | 0 ± 0.0 | 28.6 ± 3.7 |
| Headache: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 14.3 ± 0.4 |
| Headache: Moderate | 28.6 ± 3.7 | 0 ± 0.0 | 14.3 ± 0.4 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Moderate | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 14.3 ± 0.4 | 0 ± 0.0 | 28.6 ± 3.7 |
| Diarrhea: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 28.6 ± 3.7 |
| Diarrhea: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 42.9 ± 9.9 | 0 ± 0.0 | 42.9 ± 9.9 |
| New or worsened muscle pain: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 42.9 ± 9.9 |
| New or worsened muscle pain: Moderate | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 1. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Fever: Any | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Fever: >=38.0 to 38.4 deg C | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Fever: >40.0 deg C | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Fatigue: Any | 60.0 (14.7 to 94.7) | 100.0 (2.5 to 100.0) | 100.0 (2.5 to 100.0) |
| Fatigue: Mild | 40.0 (5.3 to 85.3) | 100.0 (2.5 to 100.0) | 0 (0.0 to 97.5) |
| Fatigue: Moderate | 20.0 (0.5 to 71.6) | 0 (0.0 to 97.5) | 100.0 (2.5 to 100.0) |
| Fatigue: Severe | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Fatigue: Grade 4 | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Headache: Any | 40.0 (5.3 to 85.3) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Headache: Mild | 20.0 (0.5 to 71.6) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Headache: Moderate | 20.0 (0.5 to 71.6) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Headache: Severe | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Headache: Grade 4 | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Chills: Any | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 100.0 (2.5 to 100.0) |
| Chills: Mild | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 100.0 (2.5 to 100.0) |
| Chills: Moderate | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Chills: Severe | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Chills: Grade 4 | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Vomiting: Any | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Vomiting: Mild | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Vomiting: Moderate | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Vomiting: Severe | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Vomiting: Grade 4 | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Diarrhea: Any | 40.0 (5.3 to 85.3) | 100.0 (2.5 to 100.0) | 0 (0.0 to 97.5) |
| Diarrhea: Mild | 40.0 (5.3 to 85.3) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Diarrhea: Moderate | 0 (0.0 to 52.2) | 100.0 (2.5 to 100.0) | 0 (0.0 to 97.5) |
| Diarrhea: Severe | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Any | 20.0 (0.5 to 71.6) | 100.0 (2.5 to 100.0) | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Mild | 0 (0.0 to 52.2) | 100.0 (2.5 to 100.0) | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Moderate | 20.0 (0.5 to 71.6) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Severe | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened joint pain: Any | 20.0 (0.5 to 71.6) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened joint pain: Mild | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened joint pain: Moderate | 20.0 (0.5 to 71.6) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened joint pain: Severe | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 52.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 11.1 (0.3 to 48.2) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Fever: >=38.0 deg C to 38.4 deg C | 11.1 (0.3 to 48.2) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Fever: >38.4 deg C to 38.9 deg C | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Fever: >38.9 deg C to 40.0 deg C | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Fever: >40.0 deg C | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Fatigue: Any | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 10.0 (0.3 to 44.5) |
| Fatigue: Mild | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 10.0 (0.3 to 44.5) |
| Fatigue: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Fatigue: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Fatigue: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Headache: Any | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 0 (0.0 to 30.8) |
| Headache: Mild | 0 (0.0 to 33.6) | 6.7 (0.2 to 31.9) | 0 (0.0 to 30.8) |
| Headache: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Headache: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Headache: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Chills: Any | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Chills: Mild | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Chills: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Chills: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Chills: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Vomiting: Any | 0 (0.0 to 33.6) | 13.3 (1.7 to 40.5) | 10.0 (0.3 to 44.5) |
| Vomiting: Mild | 0 (0.0 to 33.6) | 13.3 (1.7 to 40.5) | 0 (0.0 to 30.8) |
| Vomiting: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 10.0 (0.3 to 44.5) |
| Vomiting: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Vomiting: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Diarrhea: Any | 11.1 (0.3 to 48.2) | 6.7 (0.2 to 31.9) | 10.0 (0.3 to 44.5) |
| Diarrhea: Mild | 11.1 (0.3 to 48.2) | 6.7 (0.2 to 31.9) | 10.0 (0.3 to 44.5) |
| Diarrhea: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Diarrhea: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| Diarrhea: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened muscle pain: Any | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened muscle pain: Mild | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened muscle pain: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened muscle pain: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened joint pain: Any | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened joint pain: Mild | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened joint pain: Moderate | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened joint pain: Severe | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 33.6) | 0 (0.0 to 21.8) | 0 (0.0 to 30.8) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 5.3 ± 0.1 | 0 ± 0.0 | 4.5 ± 0.1 |
| Fever: >=38.0 deg C to 38.4 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 deg C to 38.9 deg C | 5.3 ± 0.1 | 0 ± 0.0 | 4.5 ± 0.1 |
| Fever: >38.9 deg C to 40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 57.9 ± 33.5 | 37.5 ± 18.8 | 45.5 ± 24.4 |
| Fatigue: Mild | 26.3 ± 9.1 | 20.8 ± 7.1 | 13.6 ± 2.9 |
| Fatigue: Moderate | 31.6 ± 12.6 | 16.7 ± 4.7 | 31.8 ± 13.9 |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 36.8 ± 16.3 | 29.2 ± 12.6 | 18.2 ± 5.2 |
| Headache: Mild | 15.8 ± 3.4 | 12.5 ± 2.7 | 4.5 ± 0.1 |
| Headache: Moderate | 21.1 ± 6.1 | 16.7 ± 4.7 | 13.6 ± 2.9 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 21.1 ± 6.1 | 4.2 ± 0.1 | 4.5 ± 0.1 |
| Chills: Mild | 10.5 ± 1.3 | 4.2 ± 0.1 | 0 ± 0.0 |
| Chills: Moderate | 10.5 ± 1.3 | 0 ± 0.0 | 4.5 ± 0.1 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 0 ± 0.0 | 12.5 ± 2.7 | 0 ± 0.0 |
| Vomiting: Mild | 0 ± 0.0 | 12.5 ± 2.7 | 0 ± 0.0 |
| Vomiting: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 5.3 ± 0.1 | 8.3 ± 1.0 | 4.5 ± 0.1 |
| Diarrhea: Mild | 5.3 ± 0.1 | 4.2 ± 0.1 | 0 ± 0.0 |
| Diarrhea: Moderate | 0 ± 0.0 | 4.2 ± 0.1 | 4.5 ± 0.1 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 10.5 ± 1.3 | 12.5 ± 2.7 | 4.5 ± 0.1 |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 4.2 ± 0.1 | 0 ± 0.0 |
| New or worsened muscle pain: Moderate | 10.5 ± 1.3 | 8.3 ± 1.0 | 4.5 ± 0.1 |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 15.8 ± 3.4 | 4.2 ± 0.1 | 4.5 ± 0.1 |
| New or worsened joint pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Moderate | 15.8 ± 3.4 | 4.2 ± 0.1 | 4.5 ± 0.1 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >=38.0 deg C to 38.4 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 deg C to 38.9 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 deg C to 40.0 deg C | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 85.7 ± 42.1 | 0 ± 0.0 | 33.3 ± 4.3 |
| Fatigue: Mild | 42.9 ± 9.9 | 0 ± 0.0 | 33.3 ± 4.3 |
| Fatigue: Moderate | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Severe | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 71.4 ± 29.0 | 0 ± 0.0 | 16.7 ± 0.4 |
| Headache: Mild | 28.6 ± 3.7 | 0 ± 0.0 | 16.7 ± 0.4 |
| Headache: Moderate | 42.9 ± 9.9 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 42.9 ± 9.9 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Mild | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Moderate | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Moderate | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 42.9 ± 9.9 | 100.0 ± 2.5 | 16.7 ± 0.4 |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 100.0 ± 2.5 | 0 ± 0.0 |
| New or worsened muscle pain: Moderate | 42.9 ± 9.9 | 0 ± 0.0 | 16.7 ± 0.4 |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Mild | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 2. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Fever: Any | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >=38.0 to 38.4 deg C | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 to 38.9 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 to 40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 60.0 ± 14.7 | 100.0 ± 2.5 | 0 ± 0.0 |
| Fatigue: Mild | 0 ± 0.0 | 100.0 ± 2.5 | 0 ± 0.0 |
| Fatigue: Moderate | 60.0 ± 14.7 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 60.0 ± 14.7 | 100.0 ± 2.5 | 0 ± 0.0 |
| Headache: Mild | 20.0 ± 0.5 | 100.0 ± 2.5 | 0 ± 0.0 |
| Headache: Moderate | 40.0 ± 5.3 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 40.0 ± 5.3 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Moderate | 40.0 ± 5.3 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 60.0 ± 14.7 | 100.0 ± 2.5 | 0 ± 0.0 |
| Diarrhea: Mild | 40.0 ± 5.3 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Moderate | 20.0 ± 0.5 | 100.0 ± 2.5 | 0 ± 0.0 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Moderate | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Moderate | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 0 ± 0.0 | 6.7 ± 0.2 | 0 ± 0.0 |
| Fever: >=38.0 deg C to 38.4 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 deg C to 38.9 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 deg C to 40.0 deg C | 0 ± 0.0 | 6.7 ± 0.2 | 0 ± 0.0 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 11.1 ± 0.3 | 6.7 ± 0.2 | 0 ± 0.0 |
| Fatigue: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Moderate | 11.1 ± 0.3 | 6.7 ± 0.2 | 0 ± 0.0 |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 0 ± 0.0 | 6.7 ± 0.2 | 0 ± 0.0 |
| Vomiting: Mild | 0 ± 0.0 | 6.7 ± 0.2 | 0 ± 0.0 |
| Vomiting: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 0 ± 0.0 | 6.7 ± 0.2 | 0 ± 0.0 |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 6.7 ± 0.2 | 0 ± 0.0 |
| New or worsened muscle pain: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 17.6 (3.8 to 43.4) | 0 (0.0 to 14.8) | 19.0 (5.4 to 41.9) |
| Fever: >=38.0 to 38.4 deg C | 11.8 (1.5 to 36.4) | 0 (0.0 to 14.8) | 14.3 (3.0 to 36.3) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 4.8 (0.1 to 23.8) |
| Fever: >40.0 deg C | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Fever: Unknown | 5.9 (0.1 to 28.7) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Fatigue: Any | 47.1 (23.0 to 72.2) | 34.8 (16.4 to 57.3) | 52.4 (29.8 to 74.3) |
| Fatigue: Mild | 35.3 (14.2 to 61.7) | 13.0 (2.8 to 33.6) | 23.8 (8.2 to 47.2) |
| Fatigue: Moderate | 11.8 (1.5 to 36.4) | 21.7 (7.5 to 43.7) | 28.6 (11.3 to 52.2) |
| Fatigue: Severe | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Fatigue: Grade 4 | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Headache: Any | 35.3 (14.2 to 61.7) | 8.7 (1.1 to 28.0) | 28.6 (11.3 to 52.2) |
| Headache: Mild | 29.4 (10.3 to 56.0) | 4.3 (0.1 to 21.9) | 9.5 (1.2 to 30.4) |
| Headache: Moderate | 5.9 (0.1 to 28.7) | 0 (0.0 to 14.8) | 19.0 (5.4 to 41.9) |
| Headache: Severe | 0 (0.0 to 19.5) | 4.3 (0.1 to 21.9) | 0 (0.0 to 16.1) |
| Headache: Grade 4 | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Chills: Any | 17.6 (3.8 to 43.4) | 4.3 (0.1 to 21.9) | 14.3 (3.0 to 36.3) |
| Chills: Mild | 5.9 (0.1 to 28.7) | 4.3 (0.1 to 21.9) | 4.8 (0.1 to 23.8) |
| Chills: Moderate | 11.8 (1.5 to 36.4) | 0 (0.0 to 14.8) | 9.5 (3.0 to 36.3) |
| Chills: Severe | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Chills: Grade 4 | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Vomiting: Any | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 4.8 (0.1 to 23.8) |
| Vomiting: Mild | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Vomiting: Moderate | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 4.8 (0.1 to 23.8) |
| Vomiting: Severe | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Vomiting: Grade 4 | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Diarrhea: Any | 11.8 (1.5 to 36.4) | 0 (0.0 to 14.8) | 4.8 (0.1 to 23.8) |
| Diarrhea: Mild | 11.8 (1.5 to 36.4) | 0 (0.0 to 14.8) | 4.8 (0.1 to 23.8) |
| Diarrhea: Moderate | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Diarrhea: Severe | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| Diarrhea: Grade 4 | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| New or worsened muscle pain: Any | 29.4 (10.3 to 56.0) | 13.0 (2.8 to 33.6) | 4.8 (0.1 to 23.8) |
| New or worsened muscle pain: Mild | 5.9 (0.1 to 28.7) | 13.0 (2.8 to 33.6) | 4.8 (0.1 to 23.8) |
| New or worsened muscle pain: Moderate | 23.5 (6.8 to 49.9) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| New or worsened muscle pain: Severe | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| New or worsened joint pain: Any | 11.8 (1.5 to 36.4) | 4.3 (2.8 to 33.6) | 4.8 (0.1 to 23.8) |
| New or worsened joint pain: Mild | 0 (0.0 to 19.5) | 4.3 (2.8 to 33.6) | 4.8 (0.1 to 23.8) |
| New or worsened joint pain: Moderate | 11.8 (1.5 to 36.4) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| New or worsened joint pain: Severe | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 19.5) | 0 (0.0 to 14.8) | 0 (0.0 to 16.1) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 42.9 (9.9 to 81.6) | 0 (0.0 to 97.5) | 33.3 (4.3 to 77.7) |
| Fever: >=38.0 to 38.4 deg C | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 33.3 (4.3 to 77.7) |
| Fever: >38.4°C to 38.9 deg C | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Fever: >38.9°C to 40.0 deg C | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Fever: >40.0 deg C | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Fatigue: Any | 85.7 (42.1 to 99.6) | 100.0 (2.5 to 100.0) | 50.0 (11.8 to 88.2) |
| Fatigue: Mild | 14.3 (0.4 to 57.9) | 100.0 (2.5 to 100.0) | 50.0 (11.8 to 88.2) |
| Fatigue: Moderate | 71.4 (29.0 to 96.3) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Fatigue: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Fatigue: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Headache: Any | 85.7 (42.1 to 99.6) | 100.0 (2.5 to 100.0) | 66.7 (22.3 to 95.7) |
| Headache: Mild | 28.6 (3.7 to 71.0) | 100.0 (2.5 to 100.0) | 33.3 (4.3 to 77.7) |
| Headache: Moderate | 57.1 (18.4 to 90.1) | 0 (0.0 to 97.5) | 33.3 (4.3 to 77.7) |
| Headache: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Headache: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Chills: Any | 71.4 (29.0 to 96.3) | 100.0 (2.5 to 100.0) | 16.7 (0.4 to 64.1) |
| Chills: Mild | 14.3 (0.4 to 57.9) | 100.0 (2.5 to 100.0) | 16.7 (0.4 to 64.1) |
| Chills: Moderate | 57.1 (18.4 to 90.1) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Chills: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Chills: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Vomiting: Any | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Vomiting: Mild | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Vomiting: Moderate | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Vomiting: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Vomiting: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Diarrhea: Any | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 33.3 (4.3 to 77.7) |
| Diarrhea: Mild | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 33.3 (4.3 to 77.7) |
| Diarrhea: Moderate | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Diarrhea: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| Diarrhea: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened muscle pain: Any | 28.6 (3.7 to 71.0) | 0 (0.0 to 97.5) | 16.7 (0.4 to 64.1) |
| New or worsened muscle pain: Mild | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 16.7 (0.4 to 64.1) |
| New or worsened muscle pain: Moderate | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened muscle pain: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened joint pain: Any | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened joint pain: Mild | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened joint pain: Moderate | 14.3 (0.4 to 57.9) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened joint pain: Severe | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 41.0) | 0 (0.0 to 97.5) | 0 (0.0 to 45.9) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 3. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Fever:Any | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Fever: >=38.0 to 38.4 deg C | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Fever: >38.4 to 38.9 deg C | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Fever: >40.0 deg C | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Fatigue: Any | 75.0 (19.4 to 99.4) | — | 0 (0.0 to 97.5) |
| Fatigue: Mild | 50.0 (6.8 to 93.2) | — | 0 (0.0 to 97.5) |
| Fatigue: Moderate | 25.0 (0.6 to 80.6) | — | 0 (0.0 to 97.5) |
| Fatigue: Severe | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Fatigue: Grade 4 | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Headache: Any | 75.0 (19.4 to 99.4) | — | 0 (0.0 to 97.5) |
| Headache: Mild | 25.0 (0.6 to 80.6) | — | 0 (0.0 to 97.5) |
| Headache: Moderate | 50.0 (6.8 to 93.2) | — | 0 (0.0 to 97.5) |
| Headache: Severe | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Headache: Grade 4 | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Chills: Any | 50.0 (6.8 to 93.2) | — | 0 (0.0 to 97.5) |
| Chills: Mild | 25.0 (0.6 to 80.6) | — | 0 (0.0 to 97.5) |
| Chills: Moderate | 25.0 (0.6 to 80.6) | — | 0 (0.0 to 97.5) |
| Chills: Severe | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Chills: Grade 4 | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Vomiting: Any | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Vomiting: Mild | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Vomiting: Moderate | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Vomiting: Severe | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Vomiting: Grade 4 | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Diarrhea: Any | 25.0 (0.6 to 80.6) | — | 0 (0.0 to 97.5) |
| Diarrhea: Mild | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Diarrhea: Moderate | 25.0 (0.6 to 80.6) | — | 0 (0.0 to 97.5) |
| Diarrhea: Severe | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| Diarrhea: Grade 4 | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Any | 50.0 (6.8 to 93.2) | — | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Mild | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Moderate | 50.0 (6.8 to 93.2) | — | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Severe | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| New or worsened joint pain: Any | 50.0 (6.8 to 93.2) | — | 0 (0.0 to 97.5) |
| New or worsened joint pain: Mild | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| New or worsened joint pain: Moderate | 50.0 (6.8 to 93.2) | — | 0 (0.0 to 97.5) |
| New or worsened joint pain: Severe | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 60.2) | — | 0 (0.0 to 97.5) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 28.6 ± 3.7 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >=38.0 to 38.4 deg C | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 to 38.9 deg C | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 to 40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 14.3 ± 0.4 | 0 ± 0.0 | 16.7 ± 0.4 |
| Fatigue: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 16.7 ± 0.4 |
| Fatigue: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 14.3 ± 0.4 | 16.7 ± 0.4 | 0 ± 0.0 |
| Chills: Mild | 0 ± 0.0 | 16.7 ± 0.4 | 0 ± 0.0 |
| Chills: Moderate | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 0 ± 0.0 | 16.7 ± 0.4 | 0 ± 0.0 |
| Vomiting: Mild | 0 ± 0.0 | 16.7 ± 0.4 | 0 ± 0.0 |
| Vomiting: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Mild | 14.3 ± 0.4 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Mild | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 de, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 8.3 ± 0.2 | 5.3 ± 0.1 | 6.7 ± 0.2 |
| Fever: >=38.0 to 38.4 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 to 38.9 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 to 40.0 deg C | 8.3 ± 0.2 | 5.3 ± 0.1 | 6.7 ± 0.2 |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Any | 50.0 ± 21.1 | 26.3 ± 9.1 | 33.3 ± 11.8 |
| Fatigue: Mild | 33.3 ± 9.9 | 10.5 ± 1.3 | 13.3 ± 1.7 |
| Fatigue: Moderate | 16.7 ± 2.1 | 15.8 ± 3.4 | 20.0 ± 4.3 |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Headache: Any | 33.3 ± 9.9 | 21.1 ± 6.1 | 13.3 ± 1.7 |
| Headache: Mild | 8.3 ± 0.2 | 15.8 ± 3.4 | 0 ± 0.0 |
| Headache: Moderate | 25.0 ± 5.5 | 5.3 ± 0.1 | 6.7 ± 0.2 |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | 6.7 ± 0.2 |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Any | 8.3 ± 0.2 | 5.3 ± 0.1 | 13.3 ± 1.7 |
| Chills: Mild | 8.3 ± 0.2 | 5.3 ± 0.1 | 0 ± 0.0 |
| Chills: Moderate | 0 ± 0.0 | 0 ± 0.0 | 13.3 ± 1.7 |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Any | 8.3 ± 0.2 | 5.3 ± 0.1 | 0 ± 0.0 |
| Vomiting: Mild | 8.3 ± 0.2 | 5.3 ± 0.1 | 0 ± 0.0 |
| Vomiting: Moderate | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Any | 25.0 ± 5.5 | 15.8 ± 3.4 | 6.7 ± 0.2 |
| Diarrhea: Mild | 25.0 ± 5.5 | 10.5 ± 1.3 | 6.7 ± 0.2 |
| Diarrhea: Moderate | 0 ± 0.0 | 5.3 ± 0.1 | 0 ± 0.0 |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Any | 16.7 ± 2.1 | 15.8 ± 3.4 | 6.7 ± 0.2 |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 15.8 ± 3.4 | 0 ± 0.0 |
| New or worsened muscle pain: Moderate | 8.3 ± 0.2 | 0 ± 0.0 | 6.7 ± 0.2 |
| New or worsened muscle pain: Severe | 8.3 ± 0.2 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Any | 25.0 ± 5.5 | 0 ± 0.0 | 6.7 ± 0.2 |
| New or worsened joint pain: Mild | 8.3 ± 0.2 | 0 ± 0.0 | 6.7 ± 0.2 |
| New or worsened joint pain: Moderate | 16.7 ± 2.1 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Fever: Any | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Fever: >=38.0 to 38.4 deg C | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Fever: >38.4 to 38.9 deg C | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Fever: >38.9 to 40.0 deg C | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Fever: >40.0 deg C | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Fatigue: Any | 50.0 (6.8 to 93.2) | 100.0 (2.5 to 100.0) | 66.7 (9.4 to 99.2) |
| Fatigue: Mild | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Fatigue: Moderate | 50.0 (6.8 to 93.2) | 100.0 (2.5 to 100.0) | 33.3 (0.8 to 90.6) |
| Fatigue: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Fatigue: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Headache: Any | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Headache: Mild | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Headache: Moderate | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Headache: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Headache: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Chills: Any | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Chills: Mild | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Chills: Moderate | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Chills: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Chills: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Vomiting: Any | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Vomiting: Mild | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Vomiting: Moderate | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Vomiting: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Vomiting: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Diarrhea: Any | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Diarrhea: Mild | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Diarrhea: Moderate | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| Diarrhea: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| Diarrhea: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| New or worsened muscle pain: Any | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| New or worsened muscle pain: Mild | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| New or worsened muscle pain: Moderate | 25.0 (0.6 to 80.6) | 0 (0.0 to 97.5) | 33.3 (0.8 to 90.6) |
| New or worsened muscle pain: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| New or worsened muscle pain: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 97.5) |
| New or worsened joint pain: Any | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| New or worsened joint pain: Mild | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| New or worsened joint pain: Moderate | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| New or worsened joint pain: Severe | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
| New or worsened joint pain: Grade 4 | 0 (0.0 to 60.2) | 0 (0.0 to 97.5) | 0 (0.0 to 70.8) |
Systemic events were recorded in an e-diary and at unscheduled clinical assessments from Day 1 to 7 after vaccination 4. Fever was defined as oral temperature \>=38.0 deg C; categorised as \>=38.0 to 38.4 deg C, \>38.4 to 38.9 deg C, \>38.9 to 40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity).Vomiting: mild: 1-2 times in 24 hours, moderate: \>2 times in 24 hours, severe: required intravenous hydration. Diarrhea: mild: 2-3 loose stools in 24 hours, moderate: 4-5 loose stools in 24 hours, severe: 6 or more loose stools in 24 hours. Grade 4 for all events: ER visit/hospitalization and were classified by investigator or medically qualified person. Events reported as AEs in the CRF within 7 days after vaccination were also included. Exact 95% CI based on Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Fever: Any | 0 ± 0.0 | 0 ± 0.0 | — |
| Fever: >=38.0 to 38.4 deg C | 0 ± 0.0 | 0 ± 0.0 | — |
| Fever: >38.4 to 38.9 deg C | 0 ± 0.0 | 0 ± 0.0 | — |
| Fever: >38.9 to 40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | — |
| Fever: >40.0 deg C | 0 ± 0.0 | 0 ± 0.0 | — |
| Fatigue: Any | 66.7 ± 9.4 | 0 ± 0.0 | — |
| Fatigue: Mild | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Fatigue: Moderate | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Fatigue: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Fatigue: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| Headache: Any | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Headache: Mild | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Headache: Moderate | 0 ± 0.0 | 0 ± 0.0 | — |
| Headache: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Headache: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| Chills: Any | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Chills: Mild | 0 ± 0.0 | 0 ± 0.0 | — |
| Chills: Moderate | 33.3 ± 0.8 | 0 ± 0.0 | — |
| Chills: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Chills: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| Vomiting: Any | 0 ± 0.0 | 0 ± 0.0 | — |
| Vomiting: Mild | 0 ± 0.0 | 0 ± 0.0 | — |
| Vomiting: Moderate | 0 ± 0.0 | 0 ± 0.0 | — |
| Vomiting: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Vomiting: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| Diarrhea: Any | 0 ± 0.0 | 0 ± 0.0 | — |
| Diarrhea: Mild | 0 ± 0.0 | 0 ± 0.0 | — |
| Diarrhea: Moderate | 0 ± 0.0 | 0 ± 0.0 | — |
| Diarrhea: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| Diarrhea: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| New or worsened muscle pain: Any | 33.3 ± 0.8 | 0 ± 0.0 | — |
| New or worsened muscle pain: Mild | 0 ± 0.0 | 0 ± 0.0 | — |
| New or worsened muscle pain: Moderate | 33.3 ± 0.8 | 0 ± 0.0 | — |
| New or worsened muscle pain: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| New or worsened muscle pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
| New or worsened joint pain: Any | 33.3 ± 0.8 | 0 ± 0.0 | — |
| New or worsened joint pain: Mild | 0 ± 0.0 | 0 ± 0.0 | — |
| New or worsened joint pain: Moderate | 33.3 ± 0.8 | 0 ± 0.0 | — |
| New or worsened joint pain: Severe | 0 ± 0.0 | 0 ± 0.0 | — |
| New or worsened joint pain: Grade 4 | 0 ± 0.0 | 0 ± 0.0 | — |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event (AE) After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=2 to <5 Years | 44.4 ± 13.7 | 33.3 ± 11.8 | 38.5 ± 13.9 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=5 to <12 Years | 36.8 (16.3 to 61.6) | 8.3 (1.0 to 27.0) | 27.3 (10.7 to 50.2) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=12 to <18 Years | 14.3 ± 0.4 | 0 ± 0.0 | 14.3 ± 0.4 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 1 to 1 Month After Vaccination 2 in Participants Aged >=18 Years | 20.0 ± 0.5 | 0 ± 0.0 | 0 ± 0.0 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=2 to <5 Years | 33.3 ± 7.5 | 40.0 ± 16.3 | 0 ± 0.0 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=5 to <12 Years | 29.4 ± 10.3 | 8.7 ± 1.1 | 4.5 ± 0.1 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=12 to <18 Years | 14.3 ± 0.4 | 0 ± 0.0 | 16.7 ± 0.4 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 3 to 1 Month After Vaccination 3 in Participants Aged >=18 Years | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=2 to <5 Years | 14.3 ± 0.4 | 16.7 ± 0.4 | 0 ± 0.0 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=5 to <12 Years | 0 ± 0.0 | 36.8 ± 16.3 | 0 ± 0.0 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event From Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=12 to <18 Years | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs after vaccination 1 to 1 month after vaccination 2 were reported in this outcome measure. Exact 2-sided CI based on the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Percentage of Participants Reporting at Least 1 Adverse Event After Vaccination 4 to 1 Month After Vaccination 4 in Participants Aged >=18 Years | 0 ± 0.0 | 100.0 ± 2.5 | — |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting Serious Adverse Events (SAEs) From Vaccination 1 Through the Duration of the Study in Participants Aged >=2 to <5 Years | 0 ± 0.0 | 53.3 ± 26.6 | 23.1 ± 5.0 |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=5 to <12 Years | 15.8 ± 3.4 | 20.8 ± 7.1 | 13.6 ± 2.9 |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant |
|---|---|---|---|
| Percentage of Participants Reporting SAEs From Vaccination 1 Through the Duration of the Study in Participants Aged >=12 to <18 Years | 0 ± 0.0 | 0 ± 0.0 | 0 ± 0.0 |
An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, and other situations as medical judgement of investigator. Exact 2-sided 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|
| Percentage of Participants Reporting SAEs From Dose 1 Through the Duration of the Study in Participants Aged >=18 Years | 20.0 ± 0.5 | 0 ± 0.0 | 100.0 ± 2.5 |
Collected over Local reactions/systemic events (systematic assessment): Day 1 to Day 7 after each dose. Non-systematic assessment: AEs were reported from Day 1 of dose 1 up to 1 month after dose 4 (approximately 9 months). For SAE, from Dose 1 on Day 1 to 6 months after Dose 4 (approximately 14 months).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| >=2 to <5 Years With Immunomodulatory Therapy | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| >=2 to <5 Years With Solid Organ Transplant | 0/15 (0%) | 8/15 (53.3%) | 13/15 (86.7%) |
| >=2 to <5 Years With Stem Cell Transplant | 0/13 (0%) | 3/13 (23.1%) | 10/13 (76.9%) |
| >=5 to <12 Years With Immunomodulatory Therapy | 0/19 (0%) | 3/19 (15.8%) | 18/19 (94.7%) |
| >=5 to <12 Years With Solid Organ Transplant | 0/24 (0%) | 5/24 (20.8%) | 23/24 (95.8%) |
| >=5 to <12 Years With Stem Cell Transplant | 0/22 (0%) | 3/22 (13.6%) | 22/22 (100%) |
| >=12 to <18 Years With Immunomodulatory Therapy | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| >=12 to <18 Years With Solid Organ Transplant | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| >=12 to <18 Years With Stem Cell Transplant | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| >=18 Years With Immunomodulatory Therapy | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| >=18 Years With Non-Small Cell Lung Cancer | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| >= 18 Years With Haemodialysis | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MelaenaGastrointestinal disorders | 0/9 | 0/15 | 0/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 1/1 |
| AzotaemiaRenal and urinary disorders | 0/9 | 0/15 | 0/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 1/1 |
| GangreneInfections and infestations | 0/9 | 0/15 | 0/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 1/1 |
| Renal colicRenal and urinary disorders | 0/9 | 0/15 | 0/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 1/5 | 0/1 | 0/1 |
| GastroenteritisInfections and infestations | 0/9 | 2/15 | 0/13 | 0/19 | 1/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 0/1 |
| Urinary tract infectionInfections and infestations | 0/9 | 2/15 | 0/13 | 1/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 0/1 |
| Dental cariesGastrointestinal disorders | 0/9 | 0/15 | 1/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 0/1 |
| BronchiolitisInfections and infestations | 0/9 | 0/15 | 1/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 0/1 |
| PyrexiaGeneral disorders | 0/9 | 0/15 | 1/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 0/1 |
| Pulmonary vein stenosisRespiratory, thoracic and mediastinal disorders | 0/9 | 1/15 | 0/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 0/1 | 0/1 |
| Event | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache (HEADACHE)Nervous system disorders | 0/9 | 1/15 | 0/13 | 11/19 | 11/24 | 9/22 | 7/7 | 1/1 | 6/7 | 4/5 | 1/1 | 0/1 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 2/9 | 3/15 | 2/13 | 5/19 | 5/24 | 2/22 | 2/7 | 0/1 | 2/7 | 3/5 | 1/1 | 0/1 |
| Myalgia (NEW OR WORSENED MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 1/9 | 1/15 | 0/13 | 6/19 | 8/24 | 3/22 | 3/7 | 1/1 | 3/7 | 2/5 | 1/1 | 0/1 |
| Urinary tract infectionInfections and infestations | 0/9 | 3/15 | 0/13 | 0/19 | 3/24 | 0/22 | 1/7 | 1/1 | 0/7 | 1/5 | 0/1 | 0/1 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 0/15 | 0/13 | 0/19 | 0/24 | 0/22 | 0/7 | 0/1 | 0/7 | 0/5 | 1/1 | 0/1 |
| Chills (CHILLS)General disorders | 2/9 | 1/15 | 1/13 | 7/19 | 3/24 | 5/22 | 5/7 | 1/1 | 1/7 | 2/5 | 0/1 | 1/1 |
| Fatigue (FATIGUE)General disorders | 3/9 | 3/15 | 3/13 | 14/19 | 17/24 | 14/22 | 6/7 | 1/1 | 5/7 | 4/5 | 1/1 | 1/1 |
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 4/9 | 3/15 | 4/13 | 16/19 | 18/24 | 19/22 | 6/7 | 1/1 | 5/7 | 4/5 | 1/1 | 1/1 |
| Swelling (SWELLING)General disorders | 1/9 | 1/15 | 1/13 | 5/19 | 4/24 | 8/22 | 2/7 | 1/1 | 2/7 | 1/5 | 0/1 | 0/1 |
| Vomiting (VOMITING)Gastrointestinal disorders | 1/9 | 3/15 | 4/13 | 2/19 | 4/24 | 1/22 | 3/7 | 0/1 | 1/7 | 0/5 | 0/1 | 0/1 |
Safety population included all participants who received at least 1 dose of study intervention. To avoid risk of identification of participant, any baseline measure data is not disclosed for reporting arm including (\>=18 Years with Non-Small Cell Lung Cancer, \>= 18 Years with Haemodialysis) and baseline measure data other than age is not disclosed for reporting arm (\>=12 to \<18 Years with Solid Organ Transplant) and reported the participant under category- Not Disclosed
| Age, Customized(Participants) | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Children (2-11 years) | 9 | 15 | 13 | 19 | 24 | 22 | 0 | 0 | 0 | 0 | 0 | 0 | 102 |
| Adolescents (12-17 years) | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 1 | 7 | 0 | 0 | 0 | 15 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 3 |
| From 65-84 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Not disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Sex/Gender, Customized(Participants) | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 8 | 3 | 12 | 9 | 5 | 2 | 0 | 5 | 3 | 0 | 0 | 51 |
| Male | 5 | 7 | 10 | 7 | 15 | 17 | 5 | 0 | 2 | 2 | 0 | 0 | 70 |
| Not disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 4 | 6 | 2 | 2 | 3 | 0 | 1 | 2 | 0 | 0 | 22 |
| Not Hispanic or Latino | 8 | 14 | 9 | 13 | 22 | 19 | 4 | 0 | 6 | 3 | 0 | 0 | 98 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Not Disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | >=2 to <5 Years With Immunomodulatory Therapy | >=2 to <5 Years With Solid Organ Transplant | >=2 to <5 Years With Stem Cell Transplant | >=5 to <12 Years With Immunomodulatory Therapy | >=5 to <12 Years With Solid Organ Transplant | >=5 to <12 Years With Stem Cell Transplant | >=12 to <18 Years With Immunomodulatory Therapy | >=12 to <18 Years With Solid Organ Transplant | >=12 to <18 Years With Stem Cell Transplant | >=18 Years With Immunomodulatory Therapy | >=18 Years With Non-Small Cell Lung Cancer | >= 18 Years With Haemodialysis | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Black or African American | 0 | 2 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 8 |
| White | 9 | 11 | 12 | 17 | 21 | 19 | 6 | 0 | 7 | 1 | 0 | 0 | 103 |
| More than one race | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 4 |
| Not disclosed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Jul 2023, 21 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 21 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine